Status:
COMPLETED
Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how pati...
Detailed Description
OBJECTIVES: * Correlate gene expression profiles with progression-free survival (PFS) of patients with stage III or IV follicular lymphoma treated with cyclophosphamide, vincristine, and prednisone w...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of follicular lymphoma
- Stage III or IV disease
- Received cyclophosphamide, vincristine, and prednisone with or without rituximab on clinical trial E-1496
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
April 18 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 11 2011
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT00898963
Start Date
April 18 2007
End Date
February 11 2011
Last Update
July 31 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.